ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
6081 articles about ACCESSWIRE
-
Results of the Combined General Meeting on April 2, 2024
4/4/2024
Biophytis SA announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting.
-
Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI
4/4/2024
Participants at HJF Medical Research International in Abuja, Nigeria, have been vaccinated in the first Phase 2 clinical trial of a Lassa fever virus (LASV) vaccine candidate to date, according to IAVI, a nonprofit scientific research organization and the trial sponsor.
-
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
4/4/2024
Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Year End Financial Results on a Conference Call on April 9, 2024 at 8:30 am Eastern Time.
-
Allara Health Announces New Study That Reveals Significant Productivity Loss Due to Polycystic Ovary Syndrome (PCOS), Highlights Racial and Mental Health Factors
4/3/2024
Allara Health released the first study to investigate the impact of Polycystic Ovary Syndrome (PCOS) on workplace productivity, led by Dr. Heather Huddleston, MD, Director of the University of California San Francisco PCOS Clinic.
-
Berlin Cures Expands Research Capabilities and Scientific Expertise with New Advisory Board
4/3/2024
Berlin Cures, a biotechnology company in Phase II clinical trial for a treatment against Long COVID, appoints six distinguished scientists to a new advisory board.
-
AlzeCure Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024
4/3/2024
AlzeCure Pharma AB announced that an abstract on its preclinical project TrkA-NAM against osteoarthritis pain and other severe pain conditions has been accepted for presentation at the IASP 2024 World Congress on Pain in Amsterdam on August 5-9.
-
Study Shows hTERT Vaccination Induces Immunological Responses and Prevents Progression in a Subset of Therapy-Resistant Poor Prognosis Cancer Patients
4/3/2024
In a significant stride towards active immune therapy of cancer, a recently featured article in Experimental Biology and Medicine (Volume 249, Issue 1) describes a Phase 1 clinical trial, led by James Spicer and colleagues at King's College London.
-
Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization
4/3/2024
Clairvoyant Therapeutics Inc. , today announced that it is on target to potentially become the first in the world to commercialize clinically validated psilocybin treatment.
-
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
4/3/2024
Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, evaluating the safety and efficacy of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), has been published in Nature.
-
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
4/3/2024
Bausch Health, Canada Inc. today announced the first public drug plan listings for Pr UCERIS (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.
-
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
4/3/2024
Aytu BioPharma, Inc. today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.
-
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis
4/2/2024
Cantargia Cantargia reported publication of promising preclinical data supporting the potential of the anti-IL1RAP antibody CAN10 as treatment of atherosclerosis.
-
StageZero Life Sciences Announces Delay to Fourth Quarter and Year End 2023 Financial Results
4/2/2024
StageZero Life Sciences, Ltd. announced a delay in the filing of its audited consolidated financial statements for the year ended December 31, 2023, management's discussion and analysis for the same period and management certifications of annual filings beyond the deadline of April 2, 2024 prescribed by Canadian securities laws.
-
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
4/2/2024
Jaguar Health, Inc. today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International.
-
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
4/2/2024
Petros Pharmaceuticals, Inc. announces positive results of an initial cohort of its self-selection study comparing the use of a Drug Facts Label (DFL) alone to a DFL in combination with a web app (technology component).
-
Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities
4/2/2024
Biotricity Inc., a leading Technology-as-a-Service company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues.
-
Repair Biotechnologies Demonstrates Rapid Reversal of Atherosclerosis in Mouse Models
4/2/2024
Repair Biotechnologies, Inc. announced today that its lipid nanoparticle (LNP)/messenger RNA (mRNA) therapy has rapidly reversed the progression of atherosclerosis in mouse models applicable to both the rare genetic condition of familial hypercholesterolemia as well as atherosclerosis in the broader population.
-
Rancho Biosciences Joins Forces With Davos Alzheimer's Collaborative in Global Fight Against Alzheimer's Disease
4/2/2024
Rancho Biosciences is excited to announce its work with the Davos Alzheimer's Collaborative (DAC), a first-of-its-kind global public-private platform leading an unprecedented response to Alzheimer's disease.
-
Gemina Laboratories Sign First Strategic License Agreement
4/2/2024
Gemina Laboratories Ltd. is pleased to announce the signing of a license agreement with a significant global diagnostics company.
-
Edesa Biotech to Participate in Upcoming Investor Conferences
4/2/2024
Edesa Biotech, Inc. announced today that Edesa management plans to participate in the following upcoming investor conferences.